|Education||SB, Massachusetts Institute of Technology|
Though cancer immunotherapy has already shown promising results in the clinic, its tremendous potential will in part be limited by the lack of truly cancer-specific antigens. Mutant epitopes encoded by cancer genes represent a means to specifically distinguish tumors from normal tissues, yet their intracellular nature prevents access by conventional targeted therapies such as antibodies. Therefore, we seek to generate antibodies reactive against commonly mutated oncogenic peptides presented by major histocompatibility complex (MHC) class I molecules that can specifically recognize or kill cancer, but not normal, cells.
- Skora AD*, Douglass J*, Hwang MS*, Tam AJ, Blosser RL, Gabelli SB, Cao J, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. Proc Natl Acad Sci U S A. 2015 Jul 27. PMID 26216968. [*equal contribution]